Immunovant (NASDAQ:IMVT) announced topline results from two Phase 3 clinical studies evaluating batoclimab in patients with active, moderate-to-severe thyroid eye disease (TED) on Thursday, April 2, 2026.
FitLife Brands (NASDAQ:FTLF) announced its financial results for the fourth quarter and full year ended December 31, 2025, on Wednesday, April 1, 2026. The results highlight a transformative period for the Omaha-based company, largely defined by the successful integration and rapid scaling of the Irwin acquisition.
IDEXX Laboratories (NASDAQ:IDXX) announced on Wednesday, April 1, 2026, the official launch of the IDEXX Cancer Dx™ Panel in the United Kingdom.
Cadrenal Therapeutics (NASDAQ:CVKD) reported its fourth-quarter and full-year 2025 financial results on Tuesday, March 31, 2026, marking a critical transition from mid-stage development to pivotal Phase 3 readiness for its lead candidate, CAD-1005.
Keenova Therapeutics (NYSE:MNK) reported robust fourth-quarter and full-year 2025 financial results on Tuesday, marking its first full quarter as a combined branded therapeutics entity following the merger of Mallinckrodt and Endo.
Xtant Medical Holdings (NYSE:XTNT) reported robust financial results for the full year 2025 on Tuesday, marked by double-digit revenue growth and a strategic pivot toward its core orthobiologics business.
Veradermics (NYSE:MANE), a late-clinical stage biopharmaceutical firm specializing in aesthetic and dermatological therapeutics, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
Connect Biopharma Holdings (NASDAQ:CNTB), a clinical-stage biopharmaceutical company focused on chronic inflammatory diseases, today reported positive topline preliminary results from its Phase 1 clinical pharmacology study (CBP-201-105) evaluating an intravenous (IV) formulation of rademikibart.
GSK (NYSE:GSK) today announced that China’s National Medical Products Administration (NMPA) has granted approval for Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype.
IDEAYA Biosciences (NASDAQ:IDYA), a leading precision medicine oncology company, today announced the first-patient-in (FPI) for its Phase 1 clinical trial evaluating the combination of IDE849 and IDE161.
enVVeno Medical (NASDAQ:NVNO), a clinical-stage medical device company developing innovative solutions for the treatment of chronic venous insufficiency (CVI), today reported its financial results for the full year ended December 31, 2025.
Humacyte (NASDAQ:HUMA), a pioneer in universally implantable, bioengineered human tissues, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
